Although the use of endocrine therapy in combination with intravenous chemotherapy has not been standardized, the combination of fulvestrant and chemotherapy may be promising. A 62-year-old woman came to our hospital's outpatient clinic with extensive ascites. Approximately 10 years earlier, she had undergone mastectomy and sentinel lymph node biopsy. Pathologically invasive lobular carcinoma, with a maximum diameter of 28 mm, had been diagnosed in the left breast. The cancer had a histological grade of 2, was positive for estrogen receptor (95% or more positive cells), and was negative for both progesterone receptor (less than 1% positive cells) and human epidermal growth factor receptor 2. For 5 years the patient underwent adjuvant endocrine therapy with tamoxifen and then with anastrozole. Four years 2 months after adjuvant endocrine therapy had been completed, she felt abdominal distention, and her symptoms gradually worsened. A series of intensive examinations indicated that the invasive lobular carcinoma had metastasized to the peritoneum, pleura, uterus, and bone.
Introduction
Fulvestrant is a selective estrogen receptor (ER) downregulator, a so-called "pure antiestrogen," that decreases ER expression with no agonistic effects 1, 2 . The expression of ER is also affected by tamoxifen, a selective ER modulator that acts as a partial agonist 1 . Although tamoxifen is effective both in premenopausal and postmenopausal women, fulvestrant is effective only in postmenopausal women 3 . Although fulvestrant has been used at a dose of 250 mg, at a dose of 500 mg fulvestrant has been shown to be more effective but no more toxic 4, 5 . Currently, the standard administration of fulvestrant is a 500-mg intramuscular injection on days 1, 15, and 29 and every 28 days thereafter.
The concurrent administration of tamoxifen and intravenous chemotherapy is no longer performed because synergistic efficacy was not demonstrated 6 . However, an oral fluorouracil prodrug, UFT (uracil and tegafur), has been used in combination with tamoxifen in adjuvant trials in Japan for patients with node-negative breast cancer 6 . In women with ER-positive breast cancer, the combination of UFT and tamoxifen seemed to yield better overall survivals than did each drug alone 7 . Currently, another oral fluorouracil prodrug, TS-1 (tegafur/gimeracil/oteracil potassium), is being investigated in a phase 3 study in Japan to determine whether its addition helps standard adjuvant endocrine therapy to inhibit recurrences in women with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (University Hospital Medical Information Network trial number, 000003969).
In an in vitro study, fulvestrant had a synergistic effect with doxorubicin, paclitaxel, docetaxel, vinorelbine, and fluorouracil; however, tamoxifen did not have such an effect 8 . Fulvestrant itself is a fully active drug that would not be expected to cause clinically significant drug interactions through the inhibition of cytochrome P450 (CYP)-mediated metabolism of co-administered agents 9 . Therefore, a concurrently administered drug is not likely to affect the safety or efficacy of fulvestrant 9 . However, tamoxifen is activated after it is metabolized to endoxifen, and its metabolic potency ranges widely due to gene polymorphism CYP2D6
10
. On the basis of these properties, fulvestrant might be a better choice than tamoxifen for use in combination with chemotherapy.
The efficacy and tolerability of the combination of fulvestrant and chemotherapy have been analyzed in only a single prospective trial. In a phase 2 trial, low doses of 1,500 mg (body weight <80 kg) or 2,000 mg of capecitabine were used in combination with a low dose (250 mg) of fulvestrant in 41 postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer 11 . The median time to progression (TTP) was 26.9 months, and the clinical benefit rate was 58.5% 11 . Accordingly, the combination of fulvestrant and capecitabine is a promising treatment for women with ER-positive, HER2-negative metastatic breast cancer.
We report a case of metastatic breast cancer in which combination treatment with fulvestrant and low-dose capecitabine was effective and tolerable.
Case
A 62-year-old woman with extensive ascites came to our outpatient clinic to consult about whether the ascites was tively, all of which were higher than normal ranges (! 5.0 ng/mL, ! 27.0 U/mL, <4.5 U/mL, and ! 35.0 U/mL, respectively) (Fig. 2) . Concentrations of CA19-9 and CA72-4 were 12.2 U/mL and 1.2 U/mL, respectively, both of which were within normal ranges (! 37.0 U/mL and ! 8.0 U/mL, respectively). Drainage of the ascites fluid had been performed twice before the patient came to our outpatient clinic; the maximal volume of drained fluid was 4,700 mL.
On the basis of the above findings, we concluded that the carcinoma of the left breast had metastasized to peritoneum, pleura, uterus, and bone. These metastatic patterns were considered typical of invasive lobular carcinoma of the breast.
A large amount of ascites fluid resulted in low activity in the patient's daily life; therefore, chemotherapy, such
as an anthracycline or a taxane, was considered. However, the primary tumor was ER-positive and HER2-negative, and the disease was not life threatening. Therefore, endocrine therapy was considered optimal as a first- 2). Therefore, anastrozole was considered to have been ineffective in the present case.
As a second-line therapy, chemotherapy was considered optimal, because anastrozole had been ineffective and the ascites should have rapidly improved. However, the patient wanted to avoid hair loss. Accordingly, fulvestrant was considered suitable as a second-line endocrine therapy; however, it was not likely to rapidly decrease the volume of the ascites. Therefore, we chose to the combination of fulvestrant and capecitabine because a phase 2 trial had found that this regimen was effective and tolerable for patients with metastatic breast cancer.
In this phase 2 trial, fulvestrant was administered at a low dose of 250 mg, and capecitabine was administered daily without interruption at low doses of 1,500 mg (body weight <80 kg) and 2,000 mg (body weight ! 80 kg).
In the present case, 500 mg of fulvestrant was intramuscularly injected on days 1, 15, and 29 and every 28 days thereafter. Capecitabine, 1,800 mg, was administered daily for 21 days followed by a 7-day rest period in a 28-day cycle. The daily dose of 1,500 mg of capecitabine administered without interruption was similar to the daily dose of 2,000 mg of capecitabine administered for 21 days in a 28-day cycle. In Japan, capecitabine is administered only with a tablet containing 300 mg. Because our patient's body weight was approximately 48 kg, 1,800 mg (6 tablets) of capecitabine was considered suitable.
After this combination therapy was started the patient felt slight improvement of abdominal distention, and by 2 weeks after the start the concentrations of CEA and CA 15-3 had decreased to 18.0 ng/mL and 106.2 U/mL, respectively, (Fig. 2) . The ascites was drained 2 times during the month after the start of combination therapy, and the maximal volume drained was 3,500 mL. No further drainage was needed. The ascites had decreased by 10 months after the start of combination therapy (Fig. 3a) , and pleural effusion had completely disappeared. Also during this time, the uterine wall became thinner (Fig. 3   b) and the endometrial cavity became smaller. Tumor markers had decreased in concentration for 10 months after the start of combined therapy (Fig. 2) . No side effects were observed by physicians or complained of by the patient during the above-described period.
Discussion
In the present case, the combination of fulvestrant and low-dose capecitabine was effective and well tolerated. capecitabine doses are changed to adjust to our administration method, 1,500 and 2,000 mg of daily capecitabine are comparable to 2,000 and 2,667 mg, respectively. Fulvestrant was administered at a higher dose in the present case than in the above phase 2 study; whereas the daily capecitabine dose of 1,800 mg in the present case was similar to the daily dose of 2,000 mg (body weight <80 kg) in the phase 2 study of Schwartzberg et al. 11 . Therefore, our combination of fulvestrant and low-dose capecitabine might have been more effective than the regimen used in the phase 2 trial.
In the present case, no adverse events were observed for 10 months after the start of the combination therapy.
Adverse events after treatment with 500 mg of fulves- , the most common side effect with a median follow-up period of 11 months, which was similar to the follow-up period of 10 months of the present case, was palmar-plantar erythrodysesthesia, which was observed . One of the most suitable agents to combine with fulvestrant, as suggested by the present case study and previous studies, is low-dose capecitabine. However, the optimal dose of capecitabine, when combined with 500 mg of fulvestrant, should be determined in future clinical trials. In conclusion, we believe that the combination of fulvestrant and low-dose capecitabine is promising, because of its efficacy and tolerability, for the treatment of patients with ER-positive, HER2-negative metastatic breast cancer.
